Sani H Kizilbash

13PUBLICATIONS
192CO-AUTHORS
Nanotoxicology, health and safetyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMining, energy and natural resources lawMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Oct 13, 2026
MGMT promoter methylation as a molecular biomarker in neuro-oncology: current practices, challenges, and future directions.

|Jul 08, 2026
EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma.

|Dec 19, 2025
Clinical Implications of Aberrant Retinoblastoma Signaling in Patients With Grade 4 IDH-Mutant Astrocytoma: A Retrospective Cohort Study.

Muhammad Asad Maqbool, Robert B Jenkins, Cristiane M Ida

|Dec 01, 2025
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

Howard Colman, Giuseppe Lombardi, Eric T Wong

|Sep 30, 2025
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.

James J Harding, Do-Youn Oh, Teresa Macarulla Mercade

|Apr 09, 2025
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements.

Seshiru Nakazawa, Federica Pecci, Igor Odintsov

Pageof 3

Frequent Collaborators

4 joint publications

Cecile Riviere-Cazaux

4 joint publications

Terry C Burns

3 joint publications

Jann N Sarkaria

2 joint publications

David M Routman